A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-22 and is reviewed periodically as new material appears.
Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised and often hygroscopic |
| Solubility class | Freely soluble in water | Poor solubility in non-polar solvents |
| Typical storage temperature | -20 degrees Celsius or colder | Sealed, desiccated, protected from light |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Establishes purity and confirms mass |
| Common salt form | Trifluoroacetate or acetate | Counterion reported alongside purity values |
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
=== PE Corporation === In 1999, to focus on the new genomics, Perkin-Elmer Corporation was renamed PE Corporation, and sold its old Analytical Instruments division to EG&G, Inc., which also acquired the Perkin-Elmer name. PE Biosystems remained with PE Corp., and became PE Biosystems Group, with 3,500 employees and net revenues of over $1.2 billion. New instruments were developed and sold for forensic human identification, protein identification and characterization, metabolite pathway identification, and lead compound identification from combinatorial libraries. On April 27, 1999, the shareholders of Perkin-Elmer Corporation approved the reorganization of Perkin-Elmer into PE Corporation, a pure-play life science company. Each share of the Perkin-Elmer stock (PKN) was to be exchanged for one share and for +1⁄2 of a share respectively of the two new common share tracking stocks for the two component Life Sciences groups, PE Biosystems Group and Celera Genomics Group. On April 28, 1999, the two replacement tracking stocks for the new PE Corporation were issued to shareholders. Dr. Michael W. Hunkapiller remained as a Senior Vice President of PE Corporation, and as president of PE Biosystems. On May 6, 1999, the recapitalization of the company resulted in issuance of the two new classes of common stock, called PE Corporation-PE Biosystems Group Common Stock and PE Corporation-Celera Genomics Group Common Stock. On that date, trading began in both new stocks on the New York Stock Exchange, to great excitement.
'Arctic Queen' or 'Polar bear' (double white) 'Clematis Josephine' or 'Clematis Evijohill' (pinkish-mauve) 'Marie Boisselot' (white) 'Miss Bateman' (white with red stamens) 'Nelly Moser' (white with pink stripes) 'Niobe' (maroon) 'The President' (blue) In the Clematis integrifolia group (or Integrifolia group) are non- or semi-climbing plants that flower on the current year's growth. These include the violet-pink 'Arabella'. In the late large-flowered group, which flower on the current year's growth, are:
Because impact factor is commonly accepted as a proxy for research quality, some journals adopt editorial policies and practices, some acceptable and some of dubious purpose, to increase their impact factor. For example, journals may publish a larger percentage of review articles which generally are cited more than research reports. Research undertaken in 2020 on dentistry journals concluded that the publication of "systematic reviews have significant effect on the Journal Impact Factor ... while papers publishing clinical trials bear no influence on this factor. Greater yearly average of published papers ... means a higher impact factor." Journals may also attempt to limit the number of "citable items"—i.e., the denominator of the impact factor equation—either by declining to publish articles that are unlikely to be cited (such as case reports in medical journals) or by altering articles (e.g., by not allowing an abstract or bibliography in hopes that Journal Citation Reports will not deem it a "citable item"). As a result of negotiations over whether items are "citable", impact factor variations of more than 300% have been observed. Items considered to be uncitable—and thus are not incorporated in impact factor calculations—can, if cited, still enter into the numerator part of the equation despite the ease with which such citations could be excluded. This effect is hard to evaluate, for the distinction between editorial comment and short original articles is not always obvious. For example, letters to the editor may be part of either class.
Sources: en.wikipedia.org
In October 2016, he was selected as a "full member" of the Royal College of Physicians of Edinburgh, one of only a handful of Turkish nationals to receive that honor, marked by a ceremony in which Okan's membership diploma was bestowed upon him by then-President of the Royal College, and later director of the National Institute for Health Research, Derek Bell. In November 2020, he was awarded an FRCP from the Royal College of Physicians of London, and in January 2021 awarded an FRCP from the Royal College of Physicians of Ireland. In his early days, he started his career as a dermatologist at Acibadem Bakirkoy Hospital and later worked Medical Park Hospital and Memorial Bahcelievler Hospital as an associate professor and also as a skin diseases specialist. He founded and chaired the Dermatology Department at Istanbul Kemerburgaz University in 2013. He volunteered with Health Volunteers Overseas as part of the Dermatology program at Preah Kossamak Hospital, Phnom Penh, Cambodia. He assisted in the training of dermatology students, provided continuing education regarding current and new trends of dermatologic diagnosis and treatment and provided training to nurses and physicians involved in dermatologic care. In 2021, Okan and his team reported their findings that psoriasis patients had unusually high levels of neurofilament and Tau protein, which act as a skeleton in the nerve cells in these patients. These levels were higher than those of non-sick individuals, especially when compared to the levels of those with severe psoriasis under the age of 40.
Scutellaria is a genus of flowering plants in the mint family, Lamiaceae. They are known commonly as skullcaps. The generic name is derived from the Latin scutella, meaning "a small dish, tray or platter", or "little dish", referring to the shape of the calyx. The common name alludes to the resemblance of the same structure to "miniature medieval helmets". The genus has a subcosmopolitan distribution, with species occurring nearly worldwide, mainly in temperate regions.
It was proposed, on the basis of these findings, that bicalutamide may act as a SARM for bone remodeling in osteoblasts, different from its antiandrogenic actions in the prostate gland. Likewise, hydroxyflutamide, the active metabolite of the related NSAA flutamide, has been found to inhibit interleukin-6 production in an androgen-responsive osteoblast cell line analogously to androgens, and hence has shown SARM-like activity in bone. In accordance with preclinical findings, bicalutamide monotherapy preserves bone mineral density in men with prostate cancer. Additionally, clinical studies have reported that combined androgen blockade (CAB) with bicalutamide helps to preserve bone parameters to a greater extent than castration monotherapy. It is notable however that in contrast to castration, bicalutamide monotherapy preserves and increases estrogen levels, and estrogens have positive effects both on bone and muscle. This may explain preservation of bone with bicalutamide monotherapy observed in animals and humans. However, it could not explain findings of improved bone parameters with bicalutamide plus castration relative to castration monotherapy, as estrogens are deprived in this context. In terms of muscle, castration and menopause reduce muscle mass in women and men, and in women, estradiol replacement therapy prevents loss of lean body mass. Conversely however, estrogen deficiency did not decrease lean body mass in men treated with a GnRH agonist and testosterone with versus without an aromatase inhibitor.
{\displaystyle {\begin{aligned}\mathrm {M} _{p}({\ce {OH}})_{q}&\leftrightharpoons \mathrm {M} _{p}({\ce {OH}})_{q-1}^{+}+{\ce {OH-}}\\K_{\mathrm {b} }&={\frac {[\mathrm {M} _{p}({\ce {OH}})_{q-1}^{+}][{\ce {OH-}}]}{[\mathrm {M} _{p}({\ce {OH}})_{q}]}}\\\end{aligned}}}
Sources: en.wikipedia.org
Sealed lyophilised powder is normally kept at minus twenty degrees Celsius or below, away from light and moisture. Vials are allowed to reach room temperature before opening to limit condensation. Repeated warming and cooling of the same vial is discouraged.
Reversed-phase HPLC establishes purity and separation from related peptides, and mass spectrometry confirms the molecular mass. Amino acid analysis can verify residue composition. No single method proves identity on its own, so the results are read together.
Yes. Residual trifluoroacetate or acetate from purification adds mass and can shift the value obtained by certain assays. Purity figures are therefore meaningful only when the counterion form is stated. Reporting both peptide content and salt form gives a clearer picture.
The dry powder is typically held at -20 degrees Celsius or lower, protected from light and moisture. Allowing a sealed vial to reach room temperature before opening reduces condensation on its contents. Conditions stated on a supplier certificate of analysis take precedence over general guidance.